Two days after joining the antibody-drug conjugate (ADC) race, Roche has signed another cancer-focused licensing deal.The Swiss pharma is handing over $66 million upfront to access Moma Therapeutics’ KnowledgeBase platform with the aim of identifying and developing “a certain number of novel drug targets involved in promoting cancer cell growth and survival,” Moma said in […]
